Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

Rang in Aktien #2305
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aktienkurs
$62.08
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$8.63B
Veränderung (1 Tag)
0.21%
Veränderung (1 Jahr)
4.60%
Land
US
Handel Cytokinetics, Incorporated (CYTK)

Kategorie

Healthcare
Aktien-Split-Historie für Cytokinetics, Incorporated (CYTK)
Die Aktie Cytokinetics, Incorporated (Symbol: CYTK) durchlief insgesamt 1 Aktiensplits.
Der letzte Aktiensplit fand am Jun 25, 2013 statt.
Eine CYTK-Aktie, die vor dem Jun 25, 2013 gekauft wurde, entspricht heute 0.16666666666667 CYTK-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
2013-06-25 1:6 x0.16666666666667 x0.16666666666667
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL